Drugs / BBM-C101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07668960 | Jun 2026 → Dec 2029 expected | cervical intraepithelial neoplasia grade 2/3 | Shanghai Mianyi Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07714577 | Jul 2026 → Aug 2030 expected | — | Tianjin First Central Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBM-C101 | “Drug: BBM-C101” NCT07714577 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT07714577 ↗ |